Inactive Instrument
Norda ASA Stock Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 53.25M 46.53M 42.94M 39.58M 74.6M 5.13B 76.25M 513M 202M 2.51B 200M 196M 8.65B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 27.43M 23.97M 22.12M 20.39M 38.43M 2.64B 39.28M 264M 104M 1.29B 103M 101M 4.45B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 46M | ||
| -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | ||
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | ||
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | ||
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | ||
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | ||
| +0.46% | -3.49% | - | - | 16.21B | ||
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | ||
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | ||
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | ||
| Average | +0.39% | +0.03% | +65.98% | +98.43% | 27.07B | |
| Weighted average by Cap. | -0.05% | -0.18% | +79.44% | +123.32% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 9.02M 7.88M 7.27M 6.7M 12.64M 869M 12.92M 86.93M 34.19M 425M 33.87M 33.13M 1.46B | 372M 38.58M 33.72M 31.11M 28.68M 54.06M 3.72B 55.26M 372M 146M 1.82B 145M 142M 6.26B |
| Net income | 31.17M 3.23M 2.83M 2.61M 2.4M 4.53M 311M 4.63M 31.18M 12.26M 153M 12.15M 11.88M 525M | 126M 13.07M 11.42M 10.54M 9.71M 18.31M 1.26B 18.71M 126M 49.54M 616M 49.08M 48M 2.12B |
| Net Debt | -311M -32.29M -28.22M -26.04M -24M -45.24M -3.11B -46.25M -311M -122M -1.52B -121M -119M -5.24B | -249M -25.82M -22.56M -20.82M -19.19M -36.17M -2.49B -36.97M -249M -97.88M -1.22B -96.96M -94.83M -4.19B |
Employees
-
















